Todos Medical Ltd. Research and Development Expense
Todos Medical Ltd. reported Research and Development Expense of $145.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-14
- Todos Medical Ltd. research and development expense for the quarter ending 2022-09-30 was $145.00K, a 12.65% decline year-over-year.
- Todos Medical Ltd. research and development expense for the quarter ending 2022-06-30 was $13.00K, a 94.56% decline year-over-year.
- Todos Medical Ltd. research and development expense for the quarter ending 2022-03-31 was $442.00K, a 38.01% decline year-over-year.
- Todos Medical Ltd. research and development expense for the quarter ending 2021-12-31 was $139.00K.
- Todos Medical Ltd. research and development expense for fiscal 2021 was $824.00K, a 91.65% decline from fiscal 2020.
- Todos Medical Ltd. research and development expense for fiscal 2020 was $9.86M, a 1204.63% increase from fiscal 2019.
- Todos Medical Ltd. research and development expense for fiscal 2019 was $756.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2022-09-30 | $145.00K 10-Q · filed 2022-11-14 | $158.00K derived: sum of 2 quarters · filed 2022-11-14 | $600.00K 10-Q · filed 2022-11-14 | $739.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-06-30 | $13.00K 10-Q · filed 2022-08-22 | $455.00K 10-Q · filed 2022-08-22 | $594.00K derived: sum of 3 quarters · filed 2022-08-22 | $760.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-03-31 | $442.00K 10-Q · filed 2022-05-16 | $581.00K derived: sum of 2 quarters · filed 2022-05-16 | $747.00K derived: sum of 3 quarters · filed 2022-11-14 | $986.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $305.00K derived: sum of 2 quarters · filed 2022-11-14 | $544.00K derived: sum of 3 quarters · filed 2022-11-14 | $824.00K 10-K · filed 2022-03-31 | |
| 2021-09-30 | $166.00K 10-Q · filed 2022-11-14 | $405.00K derived: sum of 2 quarters · filed 2022-11-14 | $685.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $239.00K 10-Q · filed 2022-08-22 | $643.00K 10-Q · filed 2022-08-22 | |||
| 2021-03-31 | $713.00K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | $9.86M 10-K · filed 2022-03-31 | ||||
| 2020-03-31 | $104.00K 10-Q · filed 2021-06-22 | ||||
| 2019-12-31 | $756.00K 10-K · filed 2021-04-21 | $755.70K 20-F · filed 2020-06-15 | |||
| 2018-12-31 | $459.18K 20-F/A · filed 2020-08-06 | ||||
| 2017-12-31 | $720.53K 20-F/A · filed 2020-08-06 | ||||
| 2016-12-31 | $317.91K 20-F · filed 2019-03-28 | ||||
| 2015-12-31 | $374.02K 20-F · filed 2018-05-15 | ||||
| 2014-12-31 | $336.47K 20-F · filed 2017-05-01 |